X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BMF-219 is an investigational, orally bioavailable, novel covalent menin inhibitor. It is being evaluated for the treatment of type 1 diabetes mellitus.
Lead Product(s): BMF-219
Therapeutic Area: Endocrinology Product Name: BMF-219
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2024
Details:
BMF-219 is an oral, Menin inhibitor small molecule drug which is under phase 1/2 clinical development for the treatment of Diabetes Mellitus, Type 1.
Lead Product(s): BMF-219
Therapeutic Area: Endocrinology Product Name: BMF-219
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
BMF-219 is a menin inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of diabetes mellitus, type 1 via oral administration.
Lead Product(s): BMF-219
Therapeutic Area: Endocrinology Product Name: BMF-219
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
BMF-500 is an investigational, novel, orally bioavailable, highly potent and selective covalent small molecule inhibitor of FLT3, which is being investigated in relapsed or refractory acute leukemia.
Lead Product(s): BMF-500
Therapeutic Area: Oncology Product Name: BMF-500
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2023
Details:
BMF-219 is a novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure type 1 diabetes. The FDA has cleared the initiation of COVALENT-112, a Phase II clinical trial.
Lead Product(s): BMF-219
Therapeutic Area: Endocrinology Product Name: BMF-219
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2023
Details:
BMF-219 an oral investigational covalent menin inhibitor. Optimized covalent inhibitors can provide better inhibition and tolerance than some conventional reversible inhibitors. BMF-219 is being developed for genetically defined AML, ALL, DLBCL, and MM patients.
Lead Product(s): BMF-219
Therapeutic Area: Endocrinology Product Name: BMF-219
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2023
Details:
BMF-500 is an investigational, novel, orally bioavailable, highly potent and selective covalent small molecule inhibitor of FLT3, which is being investigated in relapsed or refractory acute leukemia.
Lead Product(s): BMF-500
Therapeutic Area: Oncology Product Name: BMF-500
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2023
Details:
Biomea intends to use the net proceeds to fund the continued clinical development of BMF-219, an orally bioavailable, potent and selective covalent inhibitor of menin, for the treatment of patients with liquid and solid tumors, as well as patients with type 2 diabetes.
Lead Product(s): BMF-219
Therapeutic Area: Oncology Product Name: BMF-219
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $172.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 13, 2023
Details:
The net offering will be used to fund the continued clinical development of BMF-219, an orally bioavailable, potent and selective covalent inhibitor of menin, for the treatment of patients with liquid and solid tumors, as well as patients with type 2 diabetes.
Lead Product(s): BMF-219
Therapeutic Area: Oncology Product Name: BMF-219
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 29, 2023
Details:
BMF-219 an oral investigational covalent menin inhibitor. Optimized covalent inhibitors can provide better inhibition and tolerance than some conventional reversible inhibitors. BMF-219 is being developed for genetically defined AML, ALL, DLBCL, and MM patients.
Lead Product(s): BMF-219
Therapeutic Area: Endocrinology Product Name: BMF-219
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
